Luckily, the discovery of gain-of-function mutations on KIT and PDGFRA receptor genes led to a deep revolution in the knowledge of this tumor and from a poor characterized entity, GIST became a paradigm of target therapy. The gene discussed is KIT; the disease is gastrointestinal stromal tumor.